John Tomayko

1.0k total citations
18 papers, 763 citations indexed

About

John Tomayko is a scholar working on Molecular Medicine, Infectious Diseases and Epidemiology. According to data from OpenAlex, John Tomayko has authored 18 papers receiving a total of 763 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Medicine, 8 papers in Infectious Diseases and 7 papers in Epidemiology. Recurrent topics in John Tomayko's work include Antibiotic Resistance in Bacteria (10 papers), Antimicrobial Resistance in Staphylococcus (7 papers) and Antibiotics Pharmacokinetics and Efficacy (6 papers). John Tomayko is often cited by papers focused on Antibiotic Resistance in Bacteria (10 papers), Antimicrobial Resistance in Staphylococcus (7 papers) and Antibiotics Pharmacokinetics and Efficacy (6 papers). John Tomayko collaborates with scholars based in United States, United Kingdom and Australia. John Tomayko's co-authors include Barbara E. Murray, Teresa M. Coque, Steven C. Ricke, B E Murray, Aaron Dane, John Rex, Barry I. Eisenstein, Mark Goldberger, Charles Knirsch and Robert Meyer and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Clinical Microbiology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

John Tomayko

18 papers receiving 718 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Tomayko United States 14 327 234 210 196 152 18 763
Kim Credito United States 16 410 1.3× 255 1.1× 318 1.5× 165 0.8× 140 0.9× 27 776
I‐Wen Huang Taiwan 22 342 1.0× 314 1.3× 275 1.3× 168 0.9× 327 2.2× 42 1.1k
Pamela McGhee United States 14 454 1.4× 248 1.1× 222 1.1× 131 0.7× 199 1.3× 26 760
James S. Molton Singapore 13 307 0.9× 426 1.8× 215 1.0× 107 0.5× 167 1.1× 25 880
Maria M. Traczewski United States 18 312 1.0× 487 2.1× 253 1.2× 293 1.5× 155 1.0× 42 924
Jui‐Fen Lai Taiwan 19 310 0.9× 406 1.7× 277 1.3× 189 1.0× 213 1.4× 28 920
J. Prieto Spain 18 318 1.0× 300 1.3× 483 2.3× 122 0.6× 140 0.9× 79 1.0k
Guillermo Ruíz-Carrascoso Spain 17 255 0.8× 457 2.0× 235 1.1× 114 0.6× 127 0.8× 77 951
Mark W. Garrison United States 15 356 1.1× 232 1.0× 289 1.4× 296 1.5× 116 0.8× 33 909
Maria Merelli Italy 18 695 2.1× 124 0.5× 474 2.3× 137 0.7× 176 1.2× 30 1.2k

Countries citing papers authored by John Tomayko

Since Specialization
Citations

This map shows the geographic impact of John Tomayko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Tomayko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Tomayko more than expected).

Fields of papers citing papers by John Tomayko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Tomayko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Tomayko. The network helps show where John Tomayko may publish in the future.

Co-authorship network of co-authors of John Tomayko

This figure shows the co-authorship network connecting the top 25 collaborators of John Tomayko. A scholar is included among the top collaborators of John Tomayko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Tomayko. John Tomayko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Rizk, Matthew L., Sujata M. Bhavnani, George L. Drusano, et al.. (2019). Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents. Antimicrobial Agents and Chemotherapy. 63(5). 37 indexed citations
3.
Rex, John, George H. Talbot, Mark Goldberger, et al.. (2017). Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. Clinical Infectious Diseases. 65(1). 141–146. 47 indexed citations
4.
Tomayko, John, John Rex, David M. Tenero, Mark Goldberger, & Barry I. Eisenstein. (2014). The Challenge of Antimicrobial Resistance: New Regulatory Tools to Support Product Development. Clinical Pharmacology & Therapeutics. 96(2). 166–168. 13 indexed citations
5.
6.
O’Dwyer, Karen, Aaron Spivak, Karen Ingraham, et al.. (2014). Bacterial Resistance to Leucyl-tRNA Synthetase Inhibitor GSK2251052 Develops during Treatment of Complicated Urinary Tract Infections. Antimicrobial Agents and Chemotherapy. 59(1). 289–298. 73 indexed citations
7.
Rex, John, Barry I. Eisenstein, Jeff Alder, et al.. (2013). A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. The Lancet Infectious Diseases. 13(3). 269–275. 92 indexed citations
8.
Tomayko, John, et al.. (2013). The Safety and Efficacy of Topical Retapamulin Ointment Versus Placebo Ointment in the Treatment of Secondarily Infected Traumatic Lesions. Advances in Skin & Wound Care. 26(3). 113–121. 6 indexed citations
9.
Bowers, Gary D., David M. Tenero, Parul Patel, et al.. (2013). Disposition and Metabolism of GSK2251052 in Humans: A Novel Boron-Containing Antibiotic. Drug Metabolism and Disposition. 41(5). 1070–1081. 23 indexed citations
10.
Tenero, David M., Gary D. Bowers, Keith A. Rodvold, et al.. (2013). Intrapulmonary Pharmacokinetics of GSK2251052 in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 57(7). 3334–3339. 18 indexed citations
11.
Li, Gang, Fanny S Mitrani-Gold, Milena Kurtinecz, et al.. (2013). Systematic Review and Meta-Analysis of Antimicrobial Treatment Effect Estimation in Complicated Urinary Tract Infection. Antimicrobial Agents and Chemotherapy. 57(11). 5284–5290. 22 indexed citations
12.
Dellinger, R. Phillip, John Tomayko, Derek C. Angus, et al.. (2009). Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Critical Care Medicine. 37(11). 2929–2938. 53 indexed citations
13.
Coque, Teresa M., et al.. (1996). Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrobial Agents and Chemotherapy. 40(11). 2605–2609. 221 indexed citations
14.
Tomayko, John, et al.. (1996). Comparison of the beta-lactamase gene cluster in clonally distinct strains of Enterococcus faecalis. Antimicrobial Agents and Chemotherapy. 40(5). 1170–1174. 24 indexed citations
15.
Tomayko, John, P E Coudron, Sheldon M. Markowitz, et al.. (1996). Chromosomal DNA restriction endonuclease digestion patterns of beta-lactamase-producing Enterococcus faecalis isolates collected from a single hospital over a 7-year period. Journal of Clinical Microbiology. 34(8). 1892–1896. 16 indexed citations
16.
Tomayko, John & B E Murray. (1995). Analysis of Enterococcus faecalis isolates from intercontinental sources by multilocus enzyme electrophoresis and pulsed-field gel electrophoresis. Journal of Clinical Microbiology. 33(11). 2903–2907. 44 indexed citations
17.
Tomayko, John, Volkan Korten, & Barbara E. Murray. (1994). DU-6859a, a new fluoroquinolone agent comparative in vitro activity against enteric pathogens and multiresistant outpatient Escherichia coli. Diagnostic Microbiology and Infectious Disease. 20(1). 45–47. 2 indexed citations
18.
Korten, Volkan, John Tomayko, & Barbara E. Murray. (1994). Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci. Antimicrobial Agents and Chemotherapy. 38(3). 611–615. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kim Credito Breakdown of academic impact, for papers by I‐Wen Huang Breakdown of academic impact, for papers by Pamela McGhee Breakdown of academic impact, for papers by James S. Molton Breakdown of academic impact, for papers by Maria M. Traczewski Breakdown of academic impact, for papers by Jui‐Fen Lai Breakdown of academic impact, for papers by J. Prieto Breakdown of academic impact, for papers by Guillermo Ruíz-Carrascoso Breakdown of academic impact, for papers by Mark W. Garrison Breakdown of academic impact, for papers by Maria Merelli
Rankless by CCL
2026